Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

4 articles from the last 90 days matching "Idiopathic Pulmonary Fibrosis"

🔴 BreakingDrug approvalEMAYesterday

New medicine for two types of pulmonary fibrosis

The European Medicines Agency has approved a new medicine called Jascayd (nerandomilast) to treat adults with two types of lung scarring diseases: idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung disease. This approval means the medicine is now available for patients in the European Union. This is the first time this particular medicine has been approved for these conditions in Europe.

WHY IT MATTERSPatients with idiopathic pulmonary fibrosis in the EU now have access to a newly approved treatment option that may help slow lung scarring and preserve breathing ability.
💬 Ask your doctoridiopathic pulmonary fibrosisprogressive fibrosing interstitial lung disease
ResearchBIORXIV5 days ago

Preprint: Polygenic risk scores enhance the identification of carriers of monogenic forms of idiopathic pulmonary fibrosis

Scientists found that a new scoring system called a polygenic risk score (PRS) could help doctors identify which patients with idiopathic pulmonary fibrosis (IPF)—a serious lung disease where lung tissue becomes scarred—are more likely to carry rare genetic mutations. The study suggests that patients with lower PRS scores may be better candidates for genetic testing to find these rare mutations, which could improve how doctors diagnose and understand the disease.

WHY IT MATTERSIf validated, this approach could help IPF patients get faster genetic diagnoses by identifying who should be prioritized for rare variant testing, potentially leading to earlier intervention and more personalized treatment strategies.
ℹ Good to knowidiopathic pulmonary fibrosis
ResearchBIORXIVApr 5

Preprint: Burden of rare pathogenic variants suggests disrupted cytoskeletal organisation in the pathogenesis of pulmonary fibrosis

Researchers studied the genes of people with pulmonary fibrosis (a disease where lung tissue becomes scarred and stiff) to find rare genetic changes that might cause the disease. They found that problems in genes related to how cells maintain their structure may play an important role in developing pulmonary fibrosis. This discovery could help doctors better understand why some people develop this serious lung condition.

WHY IT MATTERSIf you or a family member has pulmonary fibrosis, this research could eventually help explain your genetic risk and lead to new treatments targeting the cellular structures that are damaged in this disease.
ℹ Good to knowIdiopathic Pulmonary FibrosisPulmonary Fibrosis
NewsUNITERAREApr 3

Fund Update: PAN Foundation — Idiopathic pulmonary fibrosis Fund Idiopathic pulmonary fibrosis fund is currently closed

The PAN Foundation's financial assistance program for idiopathic pulmonary fibrosis (a lung disease where lung tissue becomes scarred and stiff over time) is currently closed and is not accepting new applications. This program previously offered up to $12,000 per year to help patients pay for treatment costs. The fund status changed on April 2, 2026.

WHY IT MATTERSIf you have idiopathic pulmonary fibrosis and need help paying for medications or treatment, you cannot currently apply to this specific PAN Foundation program, so you'll need to explore other financial assistance options.
ℹ Good to knowidiopathic pulmonary fibrosis

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases